Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q2 2021 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
DESIGN THERAPEUTICS INC | 8 | Q3 2023 | 68.1% |
EFFECTOR THERAPEUTICS INC | 8 | Q3 2023 | 31.9% |
ARCELLX INC. | 7 | Q3 2023 | 72.6% |
NKARTA INC. | 6 | Q3 2023 | 8.0% |
ARS PHARMACEUTICALS INC | 4 | Q3 2023 | 11.6% |
MINERALYS THERAPEUTICS INC | 3 | Q3 2023 | 13.2% |
View SR ONE CAPITAL MANAGEMENT, LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-12 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-10 |
13F-HR/A | 2023-05-19 |
13F-HR | 2023-05-09 |
13F-HR | 2023-02-08 |
13F-HR | 2022-11-08 |
13F-HR | 2022-08-02 |
13F-HR | 2022-05-10 |
13F-HR | 2022-02-14 |
View SR ONE CAPITAL MANAGEMENT, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.